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Abstract
Background: The accumulation and aggregation of a-synuclein in nerve cells and glia are characteristic features of a
number of neurodegenerative diseases termed synucleinopathies. a-Synuclein is a highly soluble protein which in a
nucleation dependent process is capable of self-aggregation. The causes underlying aggregate formation are not yet
understood, impairment of the proteolytic degradation systems might be involved.
Methodology/Principal Findings: In the present study the possible aggregate clearing effects of the geldanamycin
analogue 17-AAG (17-(Allylamino)-17-demethoxygeldanamycin) was investigated. Towards this, an oligodendroglial cell line
(OLN-93 cells), stably expressing human a-synuclein (A53T mutation) was used. In these cells small punctate aggregates, not
staining with thioflavine S, representing prefibrillary aggregates, occur characteristically. Our data demonstrate that 17-AAG
attenuated the formation of a-synuclein aggregates by stimulating macroautophagy. By blocking the lysosomal
compartment with NH4Cl the aggregate clearing effects of 17-AAG were abolished and a-synuclein deposits were
enlarged. Analysis of LC3-II immunoreactivity, which is an indicator of autophagosome formation, further revealed that 17-
AAG led to the recruitment of LC3-II and to the formation of LC3 positive puncta. This effect was also observed in cultured
oligodendrocytes derived from the brains of newborn rats. Inhibition of macroautophagy by 3-methyladenine prevented
17-AAG induced occurrence of LC3 positive puncta as well as the removal of a-synuclein aggregates in OLN-A53T cells.
Conclusions: Our data demonstrate for the first time that 17-AAG not only causes the upregulation of heat shock proteins,
but also is an effective inducer of the autophagic pathway by which a-synuclein can be removed. Hence geldanamycin
derivatives may provide a means to modulate autophagy in neural cells, thereby ameliorating pathogenic aggregate
formation and protecting the cells during disease and aging.
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Introduction
In Parkinson’s disease (PD) the accumulation and aggregation of
a-synuclein in neurons is a characteristic feature, while a-synuclein
positive glial cytoplasmic inclusions (GCIs) originating in oligo-
dendrocytes are the histological hallmark of multiple system
atrophy (MSA), a specific adult onset neurodegenerative disease
with symptoms of Parkinsonism [1,2]. These inclusions are further
characterized by staining with antibodies against ubiquitin and a
variety of heat shock proteins (HSPs), specifically the small HSP
aB-crystallin. Various reports indicate the presence of the
microtubule associated protein tau [3,4]; for a recent review see
[5]. Also, HSP90 was found to be predominantly associated in
ubiquitinated inclusions of a-synucleinopathies [6]. HSPs partic-
ipate in protein folding, protein translocation and transport
processes. They function as molecular chaperones and guide
misfolded proteins to the proteasomal machinery for ubiquitina-
tion and degradation [7].
a-Synuclein is highly soluble and a natively unfolded protein,
which in a nucleation dependent process is capable of self-
aggregation. This may yield potentially neurotoxic non-fibrillar
oligomers or protofibrils and fibrillar aggregates with amyloid
characteristics [8,9,10]. a-Synuclein has been demonstrated to be
present in oligodendrocytes and astrocytes in normal human brain
[11] and we have shown previously that in cultured rat brain
oligodendrocytes a-synuclein mRNA and protein is present and
downregulated during culture maturation [12,13]. The mecha-
nisms underlying GCI formation are rather elusive, and the causes
of a-synuclein overexpression and aggregate formation are not yet
understood. Impairment of the proteolytic degradation systems
might contribute to pathogenic consequences [14,15]. a-Synuclein
degradation occurs by both the proteasome and autophagic
pathways within lysosomes [16,17,18,19,20] The co-chaperone
CHIP (carboxyl terminus of Hsp70-interacting protein) has been
suggested to be involved as a molecular switch between the two
degradation pathways [21]. Furthermore, extensive accumulation
of a-synuclein is associated with lysosomal alterations [22]. As we
have shown before, stable expression of a-synuclein or the A53T
mutation of a-synuclein in OLN-t40 oligodendroglial cells [23] did
not exert cytotoxic responses, but caused the formation of small
punctate non-fibrillary a-synuclein aggregates which were more
prominent in cells expressing the mutation [24].
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8753In the present study we have investigated the possible aggregate-
clearing effects of the geldanamycin analogue 17-AAG. 17-AAG is
currently in clinical trials as an anticancer drug, specifically binds
to and inhibits HSP90 [25] and triggers the activation of a heat
shock response in mammalian cells [26,27]. Our data demonstrate
for the first time that 17-AAG not only causes the upregulation of
HSPs, but also is an effective inducer of the autophagic pathway




Cell culture media were from Gibco/BRL (Grand Island, NY).
MG-132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) and proteo-
lytic substrate II (Z-Leu-Leu-Glu-AMC) were purchased from
Merck KGaA (Darmstadt, Germany). Rapamycin was purchased
from Santa Cruz (Heidelberg, Germany). Ammoniumchloride, 3-
Methyladenine (3-MA), Chloroquine, ATP and neutral red were
from Sigma (Seelze, Germany). MTT (1-(4,5-Dimethylthiazol-2-
yl)-3,5-diphenylformazan) was from USB Corporation (Cleveland,
OH, USA). 17-(Allylamino)-17-demethoxygeldanamycin (17-
AAG) was from A.G. Scientific, Inc. (San Diego, CA, USA). For
Western blot analysis the following antibodies were used, the
working dilutions are given in brackets. Rabbit polyclonal
antibody (PAb) anti-a-synuclein (SNL-4, 1:1000) was from Dr.
Viginia Lee, Philadelphia, USA. Rabbit PAb anti-myelin basic
protein (MBP) antibody (1:1000) was a generous gift of Dr. A.
McMorris (Wistar Institute, Philadelphia, PA, USA).
Monoclonal antibody (MAb) anti-a-tubulin (1:1000) was from
Sigma (Seelze, Germany). MAb anti-LC3 (1:250) was from
Nanotools (Teningen, Germany). MAb anti-aB-crystallin
(1:1000), PAb anti-HSP32/HO-1 (1:1000), MAb anti-HSP70
(1:1000) and MAb anti-HSP90 (1:1000) were from StressGen
(Ann Arbor, MI, USA). HRP-conjugated anti-mouse IgG was
from Amersham (Freiburg, Germany) and anti-rabbit IgG from
Biorad (Munich, Germany).
Cell Culture and Transfection
Cells were kept in DMEM supplemented with 10% heat-
inactivated fetal calf serum, 2 mM Glutamine, 50 U/ml penicillin
and 50 mg/ml streptomycin [28]. OLN-93 cells were cotransfected
with Tau40 cDNA and pcDNA3.1 containing the neomycin gene,
by using the calcium phosphate precipitation method [23]. After
selection in DMEM containing 1.0 mg/ml G418, the cells were
screened for tau expression by Western blot and indirect
immunofluorescence. A stable cell line was established, designated
OLN-t40, which was then infected with recombinant lentiviral
vector (Invitrogen, Grand Island, NY) to stably express human wild
typea-synucleinormutanthumanA53T a-synuclein(OLN-A53T).
Oligodendrocytes were prepared as described previously [13,29].
Briefly, primary cultures of glial cells were prepared from the brains
of 1–2-day-old Wistar rats and oligodendrocytes were mechanically
removedfromthe flasksafter6–8days.Precursorcellswerereplated
on poly-L-lysine (PLL)-coated culture dishes (2.7610
6 cells/10 cm
dish) and kept for 5–7 days in serum-free DMEM to which insulin
(5 mg/ml), transferrin (5 mg/ml), and sodium selenite (5 ng/ml)
(Roche Diagnostics, Mannheim, Germany) was added. These
cultures contain a highly enriched population of differentiated
oligodendrocytes with a mature morphology [13].
Heat Shock Treatment
Culture dishes were sealed with Parafilm and immersed for
30 min in a water bath at 44uC, as described [29]. Thereafter, the
cells were put into the incubator for 24 h of recovery. Control cells
were sealed for 30 min but remained in the incubator.
Immunoblot Analysis
Cellular monolayers of control and treated cells were washed
with PBS once, scraped off in sample buffer containing 1% SDS
and boiled for 10 min. Protein contents in the samples were
determined according to [30]. For immunoblotting, total cellular
extracts (5–20 mg protein per lane) were separated by one-
dimensional SDS-PAGE using 7.5% or 12.5% polyacrylamide
gels and transferred to nitrocellulose membranes (Whatman,
Dassel, Germany; 0.2 mm). For LC3 transfer PVDF blotting
membrane (Whatman, Dassel, Germany; 0.2 mm) was used. The
blots were saturated with TBS (20 mM Tris, 136.8 mM NaCl,
pH 7.5) containing 5% dry milk and incubated with the individual
antibodies overnight at 4uC. After washing with TBS-T (TBS with
0.1% v/v Tween 20), incubation with HRP-conjugated anti-
mouse (1:3000) or anti-rabbit IgG (1:3000) was carried out for 1 h
at RT. After washing with TBS-T, blots were visualized by the
enhanced chemiluminescence (ECL) procedure as described by
the manufacturer (Amersham, Braunschweig). All experiments
were carried out at least 3 times with similar results.
Immunocytochemistry
Cells were cultured on poly-L-lysine-coated glass coverslips
(3610
4 cells per 35 mm dish) in DMEM/10% FCS and then
subjected to ammoniumchloride, 17-AAG, 3-MA or rapamycin as
indicated. After washing with PBS, cells were fixed with 100%
icecold methanol for 7 min (for LC3) without further permeabi-
lization or with 3% paraformaldehyde and permeabilized with
0.1% Triton for 15 min. After blocking of unspecific binding sites
with 5% bovine serum albumin in PBS cells were washed three
times and incubated overnight at 4uC with the following
antibodies, the working dilutions are given in brackets: rabbit
pAb anti-a-synuclein (SNL-4; 1:400), mouse mAb a-tubulin
(1:400) or mouse mAb anti-LC3 (1:100). After washing with
PBS, cells were incubated for 1 h with Texas Red-conjugated
(1:100) and FITC-conjugated (1:100) secondary antibodies
(Jackson ImmunoResearch, West Grove, PA, USA), washed with
PBS and mounted. Nuclei were stained by 49,6-diamidino-2-
phenylindole (DAPI) (1.5 mg/ml) included in the mounting
medium (Vectashield; Vector Laboratories, Burlingame, CA,
USA). Fluorescent labeling was studied using a Zeiss epifluores-
cence microscope (Oberkochen, Germany) equipped with a digital
camera using a plan-neofluar objective (100x) or a Leica TCS SL
confocal laser scanning microscope (Wetzlar, Germany).
Proteasome Activity Assays
Proteasome activity was determined using fluorescence assays.
Post-glutamyl-peptidase-hydrolase activity of the proteasome was
assayed by fluorometric measurement of the release of 7-amido-4-
methylcoumarin from the synthetic substrate Z-Leu-Leu-Glu-
AMC (proteasome substrate II, S2). Proteasome activity was
determined in cell lysates treated with 17-AAG, which assesses if
17-AAG directly binds to the proteasome, and also in cell extracts
derived from live cells treated with 17-AAG, which assesses the
influence of 17-AAG on proteasomal activity in live cells.
Measurement of proteasome activity in cytoplasmic lysates was
carried out as described by Kumar et al. [31]. Briefly, OLN-A53T
cells were kept as described, harvested in PBS, centrifuged,
resuspended in HEPES buffer (5 mM HEPES, 1 mM EDTA,
pH 7.5) and sonicated. After centrifugation at 14.000 rpm at 4uC
for 15 min the supernatant was used to assay proteasome activity.
For each sample, protein concentration was determined by the
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bovine serum albumin as a standard. For each sample 15 mg
cellular extract was added to 5 wells of a 96-well plate containing
250 ml of HEPES buffer (20 mM HEPES, 0.5 mM EDTA,
0.035% SDS, pH 8) each. MG-132 (1 mM) or 17-AAG (50 nM)
were added to the cellular extract and incubated for 60 min. After
adding 5 ml proteasome substrate II, the contents were incubated
for additional 30 min at 37uC. Finally the hydrolysis of the
substrate was measured by a fluorometer at 380 nm excitation
wavelength and 440 nm emission wavelength.
Proteasome activity in cell lysates prepared after treatment of
live cells with 17-AAG was determined as described by Keller et al.
[32]. OLN-A53T were incubated with 17-AAG (50 nM, 24 h),
and harvested in ice cold proteolysis assay buffer containing
10 mM Tris-HCl (pH 7.2), 0.035% SDS, 5 mM MgCl2 and
5 mM ATP and sonicated. Protein concentrations of the resulting
lysates were determined by the bicinchoninic acid method (Pierce,
Rockford, IL) using bovine serum albumin as a standard. Aliquots
of 350 ml each, with a protein concentration of 1 mg/ml, were
incubated with 3.5 ml of proteasome substrate II (5 mM) at 37uC.
Fluorescence was determined after 30 min at 380 nm excitation
and 440 nm emission in a fluorescent microplate reader
(FluoroCount, Packard). Proteasomal activity was determined as
an increase in fluorescence of the reaction products. Each
experiment was repeated 3 times involving 5 samples per group.
Cytotoxicity - Assays
To assess the cytotoxic potential of the compounds, the MTT-
and Neutralred assays were carried out. Briefly, OLN cells were
plated on PLL-coated 96-microwell cell culture plates
(3610
3 cells/well) and grown in DMEM/10% FCS. Cells were
stressed for 24 h with indicated concentrations and assays were
performed.
MTT-Assay: Ten microliters of MTT solution (5 mg/ml in PBS)
was added to the wells containing 100 ml medium and plates were
incubated for 4 h. Thereafter, 100 ml of a solubilization solution
(10% sodium dodecyl sulfate in 0.01 mol/l HCl) was added and
incubated overnight to dissolve the formazan salt. Quantification
was then carried out with a microplate reader (Biorad, Munich,
Germany) at 595 nm, using a 655 nm filter as a reference. Data
are expressed as percentage of the untreated controls, and values
represent the means 6 SD of sixteen microwells each of two
independent experiments (n=32).
Neutral Red-Assay: For neutral red assay [33] cells were washed
with PBS and incubated for 3 h in medium containing neutral red
(0.005%). Cells were washed with PBS and dye was extracted with
100 ml of a mixture of 1% acetic acid and 50% methanol.
Quantification was then carried out with a microplate reader
(Biorad, Munich, Germany) at 540 nm. Data are expressed as
percentage of the untreated controls, and values represent the
means 6 SD of sixteen microwells each of two independent
experiments (n=32).
Statistics
Results are expressed as mean 6 SEM from at least three
independent experiments or as indicated. Multiple group com-
parisons were performed using one-way analysis of variance
(ANOVA) and Fisher’s least significant difference (LSD). Values of
P #0.01 were defined as statistically significant.
Results
The present investigation was carried out with oligodendroglial
OLN-93 cells, an oligodendroglial cell line established from
primary glial cultures derived from the brains of newborn rats
[28]. These cells were stably engineered to express the longest
human isoform of tau [23] and wild-type a-synuclein or the A53T
mutation. OLN-93 cells were more easily transfectable with a-
synuclein or a-synuclein mutations when tau was present,
indicating a protective role of tau. As we have shown before
stable transfection of these cells with a-synuclein or mutant a-
synuclein A53T was not cytotoxic, but caused the appearance of
small punctated a-synuclein aggregates, which were more
prominent in the cell line expressing the a-synuclein mutation,
namely OLN-A53T cells [24], which was used in the following
studies.
17-AAG Causes the Clearance of Small a-Synuclein
Aggregates and Leads to the Induction of Heat Shock
Proteins
The small punctated a-synuclein aggregates in these cells do not
stain with thioflavine S and thus represent a prefibrillary species
[24]. Tau is not a component of the prefibrillary species. Fig. 1
demonstrates that incubation of the cells with 17-AAG (50 nM) for
24 h caused morphological changes and the clearance of these
aggregates. Cells appeared more flattened and partly damaged. To
further determine the cytotoxic potential of 17-AAG in OLN-
A53T cells, cells were treated with 17-AAG at increasing
concentrations for 24 h and cell survival was analyzed. Half
maximal cytotoxicity, as determined by neutral red acid uptake or
MTT assay, was observed at a concentration of approximately
300 nM, and at a concentration of 25–50 nM about 20 per cent of
the cells were affected (Fig. 2A). Geldanamycin was similarly
cytotoxic (not shown). After 48 h of treatment with 17-AAG (25–
50 nM) no further damage was observable (Fig. 1A,c and 2A).
Geldanamycin and its analogue 17-AAG are inhibitors of
HSP90 [25], have been demonstrated to activate a heat shock
response [26,27], and possibly act through the increased
expression of molecular chaperones, in particular through
HSP70. To test if these compounds lead to the induction of HSPs
in the present cell culture system, immunoblot analysis was carried
Figure 1. Small punctated a-synuclein aggregates are removed
by 17-AAG. (A) Hoffman modulation contrast images of OLN-A53T
cells are shown. Scale bar,7 5mm. Cells were either untreated (a) or
treated with 50 nM 17-AAG for 24 h (b) or 48 h (c). (B) Cells were
subjected to indirect immunofluorescence using antibodies against a-
syn (SNL-4, red). Nuclei were stained with DAPI. Cells were either
untreated (a) or treated with 50 nM 17-AAG for 24 h (b). In c and d,
enlargements of the respective regions indicated in a and b are shown.
Scale bars,2 0mm (a, b), 2.5 mm (c, d).
doi:10.1371/journal.pone.0008753.g001
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demonstrate that 17-AAG in a concentration dependent manner,
within 24 h caused the upregulation of several HSPs, including
HSP90, HSP70, HSP32 and aB-crystallin.
The amount of ubiquitinated proteins was not changed by 17-
AAG (not shown). However, specifically the induction of HSP70,
which has been connected to the inhibition of a-synuclein fibril
formation, aggregation and toxicity [34,35], was observable but
occurred to a much lower extent than after a heat shock (44uC,
30 min, 24 h recovery) or after proteasomal inhibition by MG-132
(1 mM, 24 h) (Fig. 2B). Hence the aggregate clearing potential of
17-AAG might be causally related to other mechanisms, such as
induction of the proteolytic capacity of the cells.
Aggregate Clearance by 17-AAG Involves Lysosomal
Degradation Pathways
First we tested if 17-AAG enhances proteasomal activity in
OLN-A53T cells. Cell lysates were prepared and proteasome
activities were determined as described by [31,32]. As indicated in
Fig. 2C, 17-AAG (50 nM) did not enhance or impair proteasomal
activity, while the proteasome inhibitor MG-132 (1 mM) effectively
reduced proteasome activity by about 60–70 per cent. Further-
more, a-synuclein aggregate formation was not promoted by MG-
132 (not shown). To assess whether the aggregates were removed
by 17-AAG-stimulated lysosomal degradation, cells were treated
with the lysosomal inhibitor NH4Cl (50 mM) for 24 h either alone
or in combination with 17-AAG (50 nM). In the presence of
NH4Cl, the aggregates remained and were enlarged (Fig. 3A). This
was also observed when cells were incubated with 17-AAG and the
lysosomal inhibitor chloroquine simultaneously (data not shown).
Quantitative evaluation, as depicted in Fig. 3B, revealed that the
percentage of cells containing punctated a-synuclein aggregates in
control cells and cells treated with NH4Cl was about 90%, while in
cells treated with 17-AAG or rapamycin, an effective inducer of
autophagy [36], only 10–15% carried small aggregates (Fig. 3B).
In cultures treated with 17-AAG and NH4Cl simultaneously,
about 60% of the cells contained small aggregates. These results
indicate that 17-AAG promotes the clearance of the small a-
synuclein accumulations via lysosomal pathways.
Hence we probed for LC3, a specific marker for autophago-
somes, to test if autophagic activity was induced by 17-AAG.
During autophagosome formation endogenous LC3 is processed
to LC3-I, an 18 kDa cytosolic isoform, which is converted to LC3-
II. The latter is a membrane-bound 16 kDa isoform which
associates with the autophagosomal membranes and its amount as
compared to tubulin or actin correlates with the number of
autophagosomes [37,38]. Cells were incubated for 24 h with
increasing concentrations of 17-AAG (25–75 nM) or with 50 nM
17-AAG for 3–24 h, cell lysates were prepared and subjected to
immunoblot analysis. Fig. 4A demonstrates that 17-AAG in a
time- and concentration dependent manner markedly increased
the level of LC3-II. Quantitative evaluation indicates that this
effect is maximal after 18–24 h at a concentration of 50 nM
(Fig. 4B).
Since LC3-II itself is degraded by autophagy, we compared
LC3-II levels in the absence and presence of the lysosomal
inhibitor NH4Cl. Immunoblot analysis revealed that when cells
were incubated with 17-AAG (50 nM) in combination with
NH4Cl (50 mM) for 24, the level of LC3-II was further augmented
in comparison to the treatment with 17-AAG alone (Fig. 4C),
pointing to an enhancement of the autophagic flux by 17-AAG
[38]. Neither NH4Cl nor chloroquine (25 mM; 24 h) alone caused
the upregulation of HSP70 (Fig. 4C) or of any other HSPs tested.
Quantitative evaluation of the immunoblots indicated that in the
Figure 2. 17-AAG induces a heat shock response in OLN-A53T
cells and does not impair proteasomal activity. (A) Determination
of cytotoxic potential. Cells were exposed to different concentrations of
17-AAG as indicated. After 24 h, neutral red and MTT assays were
carried out. Values represent the mean 6 SEM of 16 microwells each of
two independent experiments (n=32). (B) Immunoblot analysis of heat
shock protein induction. Cells were treated with 17-AAG (1–200 nM,
24 h), or subjected to heat shock (HS: 44uC, 30 min, 24 h recovery) or to
MG-132 (MG: 1 mM, 24 h). Cell lysates were prepared and immunoblot
analysis was carried out with antibodies against the individual proteins
as indicated on the right. Co, untreated control. (C) Proteasomal activity
was determined in cell lysates treated with 17-AAG (lysate) and in cell
lysates prepared from 17-AAG treated live cells (cells). Cytoplasmic
lysates were incubated with the proteasomal inhibitor MG-132 (1 mM,
60 min) as a positive control, or 17-AAG (50 nM, 60 min). Cells were
treated with MG-132 (1 mM, 24 h) and 17-AAG (50 nM, 24 h). The post-
glutamyl-peptidase-hydrolase activity was determined using fluoro-
genic substrate Z-Leu-Leu-Glu-AMC (see Materials and Methods). The
cleavage of the substrate is inhibited by MG-132 but not by 17-AAG.
Data are expressed as percent of the untreated control and show the
mean 6 SEM from 3 independent experiments. Statistical evaluation
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supporting the notion that the lysosomal pathway is involved in its
degradation (Fig. 4D).
To assess if the stimulatory effects of 17-AAG on macro-
autophagy is not restricted to the oligodendroglial clonal cell line
used in this study, primary cultures of rat brain oligodendrocytes
were prepared and subjected to 17-AAG. Oligodendrocytes
treated with 17-AAG (24 h and 48 h, 40 nM) remained
morphologically intact and displayed an arborized morphology
(Fig. 5A). Immunoblot analysis further indicated that 17-AAG
(20–40 nM; 24–48 h) in oligodendrocytes increased the levels of
LC3-II (Fig. 5B). Also rapamycin (5 mM; 24 h) caused an increase
in LC3-II (Fig. 5B). Indirect immunofluorescence corroborated
this finding, demonstrating the accumulation of LC3-positive
puncta in the cell somata similarly as observed after treatment with
the macroautophagy inducer rapamycin (Fig. 5C). Similarly to
primary cultures of oligodendrocytes, 17-AAG caused a marked
increase in the level of LC3-II in OLN cells stably expressing a-
synuclein in the absence of tau (data not shown). However, both
cell culture systems do not express prefibrillary a-synuclein
aggregates under normal growth conditions, hence, OLN-A53T
Figure 4. 17-AAG leads to induction of macroautophagy in a
time and concentration dependent manner in OLN-A53T cells.
(A) Immunoblot analysis of LC3. Cell lysates were prepared from OLN-
A53T cells treated for 24 h with different concentrations of 17-AAG (25–
75 nM) and from cells treated with 50 nM 17-AAG for different times
(3 h–24 h). Immunoblot analysis was carried out with antibodies
against the individual proteins as indicated on the right. Co, untreated
control. 17-AAG causes the recruitment of LC3-II, an indicator of
macroautophagy. A representative blot of three independent experi-
ments is shown. (B) Quantitative evaluation of LC3-II protein level was
carried out by densitometric scanning of the blots. Results show the
mean 6 SEM from three independent experiments. LC3-II levels were
normalized to a-tubulin and the total amount of control was set to
100%. Statistical evaluation was carried out by ANOVA/Fisher’s LSD:
***P60.01 for 50 nM 17AAG (24 h) versus control (Co). (C) Lysosomal
inhibition augments LC3-II levels, indicating the disturbance of the
autophagic flux. Cells were treated for 24 h with 17-AAG (50 nM), or
NH4Cl (50 mM) or with a combination of both, as indicated. Cell lysates
were prepared and immunoblot analysis was carried out with
antibodies against the individual proteins as indicated on the right.
Co, untreated control. (D) Quantitative evaluation of the a-synuclein
levels. Experimental conditions as in (C). Data are the means of two
independent experiments +/2 SD.
doi:10.1371/journal.pone.0008753.g004
Figure 3. 17-AAG induced clearance of a-synuclein aggregates
is prevented by lysosomal inhibition. (A) Cells were treated either
with 50 nM 17-AAG (AAG; a–c), or with 50 mM NH4Cl (d–f) for 24 h or
with a combination of both (g–i). Cells were fixed with paraformalde-
hyde and indirect immunofluorescence staining was carried out using
antibodies against a-tubulin (a, d, g; green) and a-synuclein (b, e, h;
red). Overlay with DAPI (c, f, i). Scale bar,2 0mm. Note that in cells
treated with NH4Cl aggregates remain or are even enlarged. (B)
Quantitative evaluation of the percentage of cells expressing puntacte
a-synuclein aggregates. At least 350 cells on four cover slips each of
two independent experiments were counted. Data are expressed as per
cent of total cells +/2 SD. Experimental conditions were as in (A).
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synuclein clearance.
To evaluate the efficiency of 17-AAG in inducing the
autophagic pathway, we compared its effect to rapamycin in
OLN-A53T cells. Analysis of cell lysates by immunoblot procedure
shows that rapamycin (5–20 mM; 24 h) caused an enhancement of
LC3-II levels, however under these conditions not as efficiently as
17-AAG (50 nM; 24 h) (Fig. 6A). While proteasomal inhibition by
MG-132 (1 mM; 24 h) did not affect LC3, both lysososomal
inhibitors chloroquine (25 mM; 24 h) and NH4Cl (50 mM; 24 h)
Figure 5. 17-AAG leads to the induction of macroautophagy in
cultured rat brain oligodendrocytes. (A) Hoffman modulation
contrast images are shown. Oligodendrocytes (5 div) were prepared
from the brains of newborn rats and subjected to 50 nM 17-AAG for
24 h (c) or 48 h (d) or to 5 mM rapamycin for 24 h (b). In (a) the
untreated control is shown. Scale bar: 50 mm. (B) Immunoblot analysis
of LC3. Cell lysates were prepared from oligodendrocytes (5 div) treated
for 24 h or 48 h with different concentrations of 17-AAG (20–40 nM) or
with rapamycin (Rapa: 5 mM, 24 h). Immunoblot analysis was carried
out with antibodies against the individual proteins as indicated on the
right. Co, untreated control. (C) Oligodendrocytes (5 div) were either
untreated (Co, a–c), or treated for 24 h with 40 nM 17AAG (AAG, d–f), or
with 5 mM rapamycin (Rapa, g–i), and then subjected to indirect
immunofluorescence staining using antibodies against myelin basic
proteins (MBP, a,d,g; red) and LC3 (b,e,h; green). In c,f,i the overlays with
DAPI staining are shown. Scale bar,2 5mm.
doi:10.1371/journal.pone.0008753.g005
Figure 6. Autophagy induction by rapamycin causes aggregate
clearance similarly to 17-AAG. (A) Immunoblot analysis of LC3 and
HSP70. Cells were treated for 24 h with rapamycin (Rapa, 5–20 mM), 17-
AAG (AAG, 50 nM), ammonium chloride (AC, 50 mM), chloroquine (CQ,
25 mM) or MG-132 (MG, 1 mM) and subjected to immunoblot analysis
using antibodies against HSP70, LC3 and a-tubulin, as indicated on the
right. Co, untreated control. (B) OLN-A53T cells were untreated (Co, a–
c), or treated for 24 h with 50 nM 17-AAG (AAG, d–f) or with 20 mM
rapamycin (Rapa, g–i) and then subjected to indirect immunofluores-
cence staining using antibodies against a-tubulin (a,d,g; green) and a-
synuclein (SNL-4, b,e,h; red). In (c,f,i) the overlays with DAPI staining are
shown. Scale bar,2 0 mm. (C) Inhibition of macroautophagy by 3-
methyladenine. OLN-A53T cells were treated for 24 h with 50 nM
17AAG in combination with 3-MA (10 mM) and then subjected to
indirect immunofluorescence staining using antibodies against a-
tubulin (a) and a-synuclein (SNL-4, b). In (c) the overlay with DAPI
staining is shown. Note that the clearance of punctated a-synuclein
aggregates is inhibited by 3-MA. Scale bar,2 0mm.
doi:10.1371/journal.pone.0008753.g006
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(Fig. 6A). Furthermore, as indicated by indirect immunofluores-
cence staining, rapamycin similarly to 17-AAG promoted the
clearance of the small a-synuclein aggregates (Fig. 6B, see also
Fig. 3B). The effects of rapamycin were not accompanied by an
induction of HSP70 (Fig. 6A).
3-Methyladenine Inhibits 17-AAG Induced Autophagy
and LC3 Puncta Formation
The contribution of macroautophagy to the degradation of a-
synuclein in OLN-A53T cells was further confirmed by using the
selective inhibitor of macroautophagy, 3-methyladenine (3-MA).
In cells incubated in the presence of 17-AAG (50 nM) and 3-MA
(10 mM) simultaneously for 24 h, a-synuclein positive aggregates
remained to be present throughout the cytoplasm, and thus the
aggregate clearing effect of 17-AAG was abolished (Fig. 6C).
Immunoblot analysis of cell extracts depicted that application of 3-
MA (10 mM) alone or in combination with 17-AAG (50 nM; 7–
24 h) prevented (after 7 h) or reduced (after 24 h) the formation of
LC3-II, while the induction of HSP70 was not affected (Fig. 7A).
Additionally as demonstrated by indirect immunofluorecence
staining, in cells treated for 24 h with 17-AAG (50 nM) or
rapamycin (20 mM) alone, LC3 positive puncta had been formed
abundantly and were seen throughout the cytoplasma (Fig. 7B). In
contrast thereto in control cells and cells treated for 24 h with 3-
MA (10 mM) and 17-AAG (50 nM) in combination, LC3
immunoreactivity was rarely seen (Fig. 7B). Also, confocal
microscopy indicates that in cells after treatment with 17-AAG,
a-synuclein immunoreactivity occasionally was detectable in close
proximity or in colocalization with LC3-positive vesicles (Fig. 7C).
Discussion
a-Synuclein is the major building block of Lewy bodies in PD
and glial cytoplasmic inclusions in MSA [39]. Abnormal
deposition of a-synuclein has been linked to the pathogenesis of
neurodegenerative diseases, and missense mutations of the human
gene, such as A53T, increase the probability of aggregate
formation (for review see, [40,41]. It has been hypothesized that
the accumulation of prefibrillary oligomers, which provide the
intermediates for fibrillary aggregates or inclusion bodies, are the
toxic species and cause neurodegeneration [8,40,42]. Cells are
capable of clearing oligomeric a-synuclein intermediates, and
lysosomal pathways have been suggested to be mostly responsible
for clearance of oligomers but not for fibrillar inclusion bodies
[18]. Thus, stimulation of lysosomal pathways may be an effective
therapeutic approach to prevent a-synuclein oligomer toxicity and
accumulation.
Autophagy is a lysosomal pathway for degrading organelles and
long-lived proteins. The three main types of autophagy are
chaperone mediated autophagy (CMA), microautophagy and
macroautophagy [15]. CMA involves the translocation of cytosolic
proteins with a specific pentapeptide motif across the lysosomal
membrane and this process requires the action of a number of
cytosolic and lysosomal chaperones. In microautophagy small
cytoplasmic contents are introduced into the lysosomes in a
process which has been mainly characterized in yeast. Macro-
autophagy, often referred to only as autophagy, is a pathway by
which organelles and parts of cytoplasm containing proteins are
sequestered into a vesicle, termed autophagosome. After fusion of
the autophagosome with the lysosome the contents are degraded
[15,43]. An equilibrium exists between autophagosome formation
and lysosomal clearance, which has been termed autophagic flux
[44,45]. Autophagy can function as a cytoprotective response and
is particularly crucial in the aging brain and during neurodegen-
eration [46]. a-Synuclein can be degraded either by the
proteasome or by autophagy. Both macroautophagy and CMA
have been reported to contribute to a-synuclein degradation
[17,20,47,48], however the clearance of mutant a-synuclein by
CMA seems to be impaired [19].
Figure 7. 17-AAG and rapamycin promote the accumulation of
LC3-II and the formation of LC3 positive puncta which is
inhibited by 3-MA. (A) Immunoblot analysis of LC3 and HSP70. Cells
were treated with 17-AAG (AAG, 50 nM), rapamycin (20 mM), or 3-
methyladenine (3-MA, 10 mM) or with a combination of 17-AAG and 3-
MA for 7 h and 24 h, respectively. Cell lysates were prepared and
immunoblot analysis was carried out with antibodies against the
individual proteins as indicated on the right. Co, untreated control. (B)
OLN-A53T cells were either untreated (Co, a–c), or treated for 24 h with
50 nM 17AAG (AAG, d–f), or with a combination of 50 nM 17AAG and
10 mM 3-methyladenine (3-MA, g–i), or with 20 mM rapamycin (Rapa, j–
l), and then subjected to indirect immunofluorescence staining using
antibodies against a-synuclein (SNL-4, a,d,g,j; red) and LC3 (b,e,h,k,
green). In (c,f,i,l) the overlays with DAPI staining are shown. Scale bar,
25 mm. (C) Confocal images of cells treated with 17-AAG as in (B, d–f)
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synuclein or the A53T mutated form leads to the accumulation of
small punctate aggregates throughout the cytoplasm, which are
more abundant in cells expressing the A53T mutation, but do not
exert cytotoxic effects per se. These aggregates do not stain with
thioflavine S [24] and thus represent non-fibrillar inclusions which
might precede and are a requirement for the formation of fibrillary
deposits, as has been described in COS-7 cells transiently
transfected with a-synuclein [42]. Our study demonstrates that
the geldanamycin analogue 17-AAG attenuates the formation of
these small aggregates and that lysosomal and not proteasomal
pathways are involved. By blocking the lysosomal compartment
with NH4Cl or chloroquine, the aggregate clearing effects of 17-
AAG were diminished and a-synuclein deposits were even
enlarged, while on the other hand inhibition of the proteasomal
activity by MG-132 did not have this effect. Analysis of LC3-II
immunoreactivity, which is an indicator of autophagosome
formation, further revealed that induction of macroautophagy
was involved in the aggregate-clearing effects of 17-AAG. This
conclusion is supported by the finding that the specific inhibitor of
macroautophagy 3-MA prevented 17-AAG induced occurrence of
LC3 positive puncta and removal of a-synuclein aggregates.
The capability of 17-AAG to enhance macroautophagy was
further demonstrated in cultured oligodendrocytes derived from
the brains of newborn rats. Under normal growth conditions and
in the healthy human brain oligodendrocytes do not contain a-
synuclein aggregates. However, under pathological conditions and
in MSA filamentous a-synuclein inclusions are present in the
oligodendroglial cytoplasm and the disease has been suggested to
represent an oligodendroglia synucleinopathy [2]. In this respect,
the finding that 17-AAG has the capacity to induce the autophagic
pathway in oligodendrocytes might be of special interest as a
therapeutic intervention.
The HSP90 inhibitor geldanamycin and its derivative 17-AAG
modulate HSP90 function and facilitate the degradation of HSP90
client proteins [49,50]. Geldanamycin has been demonstrated to
activate a heat shock response and to suppress huntingtin protein
aggregation in a cell culture model of Huntington’s disease [26].
The stimulation of heat shock gene transcription was also
attributed to its ability to protect the brain from focal ischemia
[51], and geldanamycin was shown to restore a defective heat
shock response in vivo [52]. Suppression of a-synuclein aggrega-
tion and toxicity by geldanamycin was observed in human H4
neuroglioma cells [27]. Furthermore, it prevented from a-
synuclein toxicity in a transgenic fly model despite the continuous
presence of aggregate pathology [53,54]). These reports suggested
that geldanamycin exerts its effects by upregulation of HSP70
expression. In another study, HSP70 overexpression in mice has
been demonstrated to reduce a-synuclein aggregation and in vitro
caused a reduction in the insolubility of a-synuclein [35]. Also,
HSP70 may reduce a-synuclein fibril formation by binding
preferentially to prefibrillar species [34]. On the other hand,
HSP27 and not HSP70 exerted a potent protective effect against
a-synuclein mediated cell death in mammalian neuronal cells [55].
Our data show that HSPs and specifically HSP70 are indeed
induced by 17-AAG, but to a much lesser extent than after a heat
shock or by the proteasome inhibitor MG-132, and neither
rapamycin nor 3-MA modulate the heat shock response.
Rapamycin did not cause the induction of HSPs, and 3-MA
prevented the aggregate clearing effects of 17-AAG without
interfering with HSP70 induction. This suggests that HSP70 may
contribute but is not the major player in this context, and that 17-
AAG-induced clearance of a-synuclein aggregates is causally
related mainly to its autophagy stimulating activity. The notion
that in the fly model a concentration of geldanamycin not leading
to the induction of HSP70 was sufficient to protect neurons against
a-synuclein toxicity [53], sustains this assumption. Hence
geldanamycin and its less toxic derivatives [56] may provide a
means to remove the pathological oligomeric species of a-
synuclein, thereby ameliorating pathogenic aggregate formation
and protecting the cells during disease and aging.
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